• **Name:** **Helena A. Yu**

• **Current Position & Affiliation:** **Assistant Attending, Memorial Sloan Kettering**

• **Country:** **USA**

• **Educational Background:**

Institution and Location	Degree	MM/YY	Field of Study
Cornell University, NY	B.A,	05/03	Psychology
University of Michigan Medical School, MI	M.D.	05/07	Medicine
Hosp. of the University of Pennsylvania., PA		06/07-06/10	Internal Medicine
Memorial Sloan Kettering Cancer Center, NY		07/10-06/13	Medical Oncology

• **Professional Experience:**

Dates	Position	Department	Institution
2019-	Section Head Targeted therapy	Thoracic Oncology	Memorial Sloan Kettering Cancer Center NY,NY
2016-	Asst. Attdng	Medical Oncology	Memorial Sloan Kettering Cancer Center NY,NY
2013-	Asst. Attdng	Medical Oncology	Weill Cornell Medical College
2013-2016	Asst Attdng, L1	Medical Oncology	Memorial Sloan Kettering Cancer Center NY,NY
2010-2013	Fellow	Medical Oncology	Memorial Sloan Kettering Cancer Center NY,NY
2008-2010	Resident	Internal Medicine	Hosp of the University of Penn, Philadelphia, PA
2008-2008	Intern	Internal Medicine	Hosp of the University of Penn, Philadelphia, PA

Honors/Fellowships

2018 Solid Tumor Teaching Award, MSKCC
2011- 2012 Chief Fellow, Memorial Sloan Kettering Cancer Center, NY
2007 Graduated with distinction, University of Michigan Medical School, MI
2007 Alpha Omega Alpha, University of Michigan Medical School, MI
2006-2007 Senior Internal Medicine Scholarship, U of Michigan Medical School, MI
2003-2004 Vida Scholarship, University of Michigan Medical School, MI
2003 Magna Cum Laude- Cornell University

• **Main Scientific Publications:**

Peer-reviewed

Identified new treatment strategies that improve the outcome of patients with EGFR-mutant lung cancers

After progression on EGFR inhibitor monotherapies, there are no approved treatments. I have assessed multiple new treatments to improve outcomes for patients with EGFR-mutant lung cancers. I studied novel agents and combinations including ASP8273, erlotinib with ruxolitinib, erlotinib with AUY922, osimertinib with bevacizumab. I also am interested alternative dosing of EGFR TKIs based on mathematical modeling to attempt to delay resistance to therapy. I pioneered the use of local therapy to address oligoprogressive disease on EGFR TKIs.

Yu HA, Schoenfeld AJ, Kim R, Makhnin A, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RY, Arcila AE, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. Osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancer. JAMA Oncology. 2020, in press.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. A phase 1, dose escalation study of Oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations. Clin Cancer Res. 2017 Dec 15; 23(24):7467-7473. PMID: 28954786

Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ. Phase 1 study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients with EGFR-mutant lung cancer. Annals of Oncology 2017 Geb 1;28*2):278-285. PMID:28073786

Johnson ML*, **Yu HA***, Hart E, Weitner BB, Rademaker F, Patel JD, Kris MG, Riely GJ. A phase 1/2 study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Journal of Clinical Oncology, 2015 April 13, pii: JCO.2014.59.7328 **(*denotes co-first authors).** PMID: 25870087

Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in *EGFR* mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology 2013 March; 8(3): 346-351. PMID: 23407558

KSMO 2020 Secretariat: P&M, 3F, MS B/D, 12, Eonju-ro 79-gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX: +82-2-557-8428 E-mail: exhibit@ksmoconference.org